Management of hepatitis C

Journal of Hepatology, Supplement

Volumn 38, Issue 1, 2003, Pages

  Alberti, Alfredo ^a,b   Benvegnù, Luisa ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON; HEPATITIS C VACCINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; IRON; PEGINTERFERON; UNCLASSIFIED DRUG;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CHRONIC HEPATITIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS DIAGNOSIS; ALCOHOL CONSUMPTION; CHRONIC ACTIVE HEPATITIS; CLINICAL FEATURE; DRUG BIOAVAILABILITY; ENVIRONMENTAL FACTOR; HEMOCHROMATOSIS; INFECTION RISK; IRON METABOLISM; IRON OVERLOAD; LIVER FIBROSIS; RELAPSE; RNA ANALYSIS; VIRUS ETIOLOGY; VIRUS IDENTIFICATION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ACUTE DISEASE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS;

EID: 0037221473     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998;143:2493-2503.
2. Major M, Feinstone SM. The molecular biology of hepatitis C. Hepatology 1997;25:1527-1538.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
4. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997;229:68-76.
5. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185-194.
6. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-115.
7. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77-81.
8. Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001;284:1-12.
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS, Hepatitis C. viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-107.
10. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
11. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-1974.
12. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpoldeer JC, et al. The outcome of acute hepatitis C predicted by evolution of the viral quasisipecies. Science 2000;288:339-344.
13. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.
14. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-375.
15. Monto A, Alonzo J, Watson JJ, Grunfeld G, Wright TL. Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-736.
16. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-S34.
17. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;36:S93-S98.
18. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, et al. Clinical utility of total hepatitis C virus (HCV) core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002;36:211-218.
19. Pawlotsky J-M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36:S65-S73.
20. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
21. Layden JE, Layden TJ. How can mathematics help us understand HCV? Gastroenterology 2001;120:1546-1549.
22. Jessner W, Gschwantler M, Steindl-Numda P, Hofer H, Watkins-Reidel T, Wrba F, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001;358:1241-1242.
23. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis treated with standard and peginterferon alpha-2a. Hepatology 2001;120:1438-1447.
24. Davis G. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:S145-S151.
25. McHutchison J, Davis GL, Esteban-Mur R, Poynard T, Ling MH, Garaud JJ, Albrecht J. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alpha-2b alone or in combination with ribarivin. Hepatology 2001;34:244A.
26. Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV-RNA at the end of treatment. Am J Gastroenterol 2001;96:2968-2972.
27. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000;32:818-823.
28. Muerhoff AS, Jiang L, Shah DO, Gutierrez RA, Patel J, Garolis C, et al. Detection of HCV core antigen in human and plasma with an automated chemiluminescent immunoassay. Transfusion 2002;42:349-356.
29. Scognamiglio P, Accapezzato D, Casciaro MA, Caccaini A, Artini M, Bruno G, et al. Presence of effector CD8 + T cells in HCV exposed healthy seronegative donors. J Immunol 1999;162:6681-6689.
30. Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, et al. Clinical outcome of hypogammaglobulinemic patients following an outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 1997;110:4-8.
31. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans. Summary of a workshop. Gastroenterology 2000;119:1385-1396.
32. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
33. Gerlach JT, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, Schraut W, et al. Acute hepatitis C: natural course and response to antiviral treatment [abstract]. Hepatology 2001;34:341A.
34. Villano SA, Vlahov D, Nelson KE, Cohn S, Homas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
35. Thimme R, Oldach D, Chang K-M, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
36. Alberti A, Boccato S, Vario A, Benvegnù L. Therapy of acute hepatitis C. Hepatology 2002;36:S195-S200.
37. Alberti A, Chemello L, Belussi F, Pontisso P, Tsiminetsky S, Gerotto M, et al. Outcome of acute hepatitis C and role of alpha interferon therapy. In: Nishioka KSH, Oda T, et al., editors. Viral hepatitis and liver disease, Tokyo: Springer, 1994. p. 604.
38. Ohnishi K, Nomura F, Nakano M. Interferon therapy for acute post-transfusion non-A, non-B hepatitis: response with respect to antihepatitis C virus antibody status. Am J Gastroenterol 1991;86:1041-1049.
39. Gerlach TJ, Zachoval R, Gruener N, Jung M-C, Ulsenheimer A, Schraut W, et al. Acute hepatitis C: natural course and response to antiviral treatment. Hepatology 2001;34:341A.
40. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999;31(Suppl I):17-24.
41. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46.
42. Koretz RL, Abbey H, Coleman E, Gitnick G. NANB post-transfusion hepatitis: looking back on the second decade. Ann Intern Med 1993;119:110-115.
43. Tremolada F, Cassin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of NANB (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-281.
44. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991;14:969-974.
45. Rodger AJ, Roberts S, Lanigan A, Bowden S, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971-1975. Hepatology 2000;32:582-587.
46. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. J Am Med Assoc 2000;284:450-456.
47. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcome after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
48. Wiese M, Berr F, Lafrenz M, Porst H, Olsen V. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-96.
49. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:764-767.
50. Alberti A, Boccato S, Ferrari A, Benvegnù L, Pontisso P, Noventa F, Gatta A. Outcome of initially mild chronic hepatitis C. Hepatology 2001;34:225A.
51. Wiley TE, Brown J, Chan J. Hepatitis C virus infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700-706.
52. Fleckenstain JF, Ismail MK, Bockhold K, Van Leeuwen D, Riely CA, Waters B, South Central Liver Study Group. Africa American response rate to therapy for hepatitis C. Hepatology 1998;28:482.
53. Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger BF, Seeff LB. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120-124.
54. Alric L, Fort M, Izopet J, Vinel J-P, Charlet J-P, Selves JP, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus. Gastroenterology 1997;113:1675-1681.
55. Kunzler S, Baumann M, Schirmacher F, Dries V, Bayer E, Gerken H-P, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β. J Virol 2001;8:430-437.
56. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis. Hepatology 2000;31:828-833.
57. Smith BC, Grove J, Guzail M, Day CP, Daly AR, Burt AD, Bassendine M. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
58. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-252.
59. Negro F, Samii K, Rubbia-Brandt L, Quadri L, Male PJ, Zarski JP, et al. Haemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000;60:21-27.
60. Alberti A, Vario A, Boccato S, Pistis R, Ferrari A. Pathogenesis and incidence of hepatic steatosis in hepatitis C. 2002; submitted.
61. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:8037-8842.
62. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radoasvljevic M, Osterreicher C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002;93:2880-2885.
63. Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
64. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-333.
65. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001;21:266-271.
66. Pontisso P, Gerotto M, Benvegnu L, Chemello L, Alberti A. Co-infection by hepatitis B virus and hepatitis C virus. Antiviral Ther 1998;3:137-142.
67. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36:S201-S209.
68. Peters MG, Terrault N. Alcohol use and hepatitis C. Hepatology 2002;36:S220-S225.
69. Bacon BR. Treatment of patients with hepatitis C and Normal serum aminotransferase levels. Hepatology 2002;36:S179-S184.
70. Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10 year follow-up study. J Gastroenterol Hepatol 2001;16:536-540.
71. Rumi MG, De Filippi F, Donato MF, Del Ninno E, Colombo M. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002;9:71-74.
72. National Institutes of Health Consensus Development Conference. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 2002;36:S3-S20.
73. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56.
74. Ghany MG, Kleiner DE, Alter HJ, Doo E, Khokhar F, Park Y, et al. Progression of fibrosis in early stages of chronic hepatitis C. Hepatology 2000;32:496A.
75. Marcellin P, Akrémi R, Cazals D, Boyer N, Aupérin A, Vidaud D, Degott C. Genotype 1 is associated with a slower progression of fibrosis in untreated patients with mild chronic hepatitis [abstract]. J Hepatol 2001;34(Suppl 1):159.
76. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
77. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
78. Lindsay KL, Trepo C, Heintges T, Shiffman M, Gordon SC, Hoefs JC, et al. A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
79. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
80. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
81. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, et al. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002;36(Suppl 1):3.
82. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al. Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
83. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, et al. Interferon and ribavirin vs. interferon alone in the re-treatment of chronic hepatitis C previously non responsive to interferon. J Am Med Assoc 2001;285:193-199.
84. Jacobsen I. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy nonresponders. Gastroenterology 2002;122:A626.
85. Shiffman ML. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long term treatment against cirrhosis (HALT-C) trial [abstract]. Hepatology 2002;36:295A.
86. Hinrichsen H. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1 [abstract]. Hepatology 2002;36:379A.
87. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36:S128-S134.
88. Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol 2002;37:684-695.
89. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140.
90. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-1298.
91. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997;158:1231-1237.
92. Sjolander A, Cox J. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Deliv Rev 1998;34:321-338.
93. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-698.
94. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
95. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E, Martin-Vega C, Rosell M, Allende H, Vidal X, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-449.
96. Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, Balart L. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997;92:1788-1792.
97. Kolho E, Farkkila M, Makinen J, Krusius T, Naukkarinen R, Ikkala E. Clinical significance of hepatitis C antibodies in blood donors. J Med Virol 1994;43:129-134.
98. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994;19:871-875.
99. Okanoue T, Yasui K, Sakamoto S, Minami M, Nagao Y, Itoh Y, Kagawa K, Kashima K. Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 1996;16:241-247.
100. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
101. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, Bellis L, Precone DF, Corvisieri P, Puoti M, Minola E, Gaeta GB. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002;37:117-123.
102. Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996;110:291-295.
103. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-337.
104. Shindo M, Arai K, Okuno T. The virological and histological states of anti-HCV-positive subjects with normal liver biochemical values. Nippon Rinsho 1995;53:565-571.
105. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti B, Civardi E, Salvaneschi L, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285-290.
106. Yuki N, Hayashi N, Moribe T, Matsushita Y, Tabata T, Inoue T, Kanazawa Y, Ohkawa K, Kasahara A, Fusamoto H, Kamada T. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology 1997;25:439-444.